FDA DEVICE FACTS
Halyard Purple Nitrile Max Powder-Free Exam Gloves for Use with Chemotherapy Drugs
Owens & Minor Halyard, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The Halyard Purple Nitrile Max Powder-Free Nitrile Exam Glove is a disposable device intended for medical purposes that is worn on the examiner’s hand to prevent contamination between patient and examiner. These gloves were tested for use with the following chemotherapy drugs:
• Arsenic Trioxide (1 mg/ml) No breakthrough up to 240 minutes
• Azacitidine (Vidaza) (25 mg/ml) No breakthrough up to 240 minutes
• Bendamustine (5 mg/ml) No breakthrough up to 240 minutes
• Bortezomib (Velcade) (1 mg/ml) No breakthrough up to 240 minutes
• Bleomycin sulfate (15 mg/ml) No breakthrough up to 240 minutes
• Busulfan (6 mg/ml) No breakthrough up to 240 minutes
• Carboplatin (10 mg/ml) No breakthrough up to 240 minutes
• Carlzomib (2 mg/ml) No breakthrough up to 240 minutes
• Cetuximab (Erbitux) (2 mg/ml) No breakthrough up to 240 minutes
• Cisplatin (1 mg/ml) No breakthrough up to 240 minutes
• Cladribine (1.0 mg/ml) No breakthrough up to 240 minutes
• Cyclophosphamide (20 mg/ml) No breakthrough up to 240 minutes
• Cytarabine HCL (100 mg/ml) No breakthrough up to 240 minutes
• Cytovene (10 mg/ml) No breakthrough up to 240 minutes
• Dacarbazine (10 mg/ml) No breakthrough up to 240 minutes
• Daunorubicin HCL (5 mg/ml) No breakthrough up to 240 minutes
• Decitabine (5 mg/ml) No breakthrough up to 240 minutes
• Docetaxel (10 mg/ml) No breakthrough up to 240 minutes
• Doxorubicin HCL (2 mg/ml) No breakthrough up to 240 minutes
• Epirubicin (Ellence) (2 mg/ml) No breakthrough up to 240 minutes
• Etoposide (20 mg/ml) No breakthrough up to 240 minutes
• Fludarabine (25 mg/ml) No breakthrough up to 240 minutes
• Fluorouracil (50 mg/ml) No breakthrough up to 240 minutes
• Fulvestrant (50 mg/ml) No breakthrough up to 240 minutes
• Gemcitabine (38 mg/ml) No breakthrough up to 240 minutes
• Idarubicin (1 mg/ml) No breakthrough up to 240 minutes
• Ifosfamide (50 mg/ml) No breakthrough up to 240 minutes
• Irinotecan (20 mg/ml) No breakthrough up to 240 minutes
• Mechlorethamine HCL (1 mg/ml) No breakthrough up to 240 minutes
• Melphalan (5 mg/ml) No breakthrough up to 240 minutes
• Methotrexate (25 mg/ml) No breakthrough up to 240 minutes
• Mitomycin-C (0.5 mg/ml) No breakthrough up to 240 minutes
• Mitoxantrone (2 mg/ml) No breakthrough up to 240 minutes
• Oxaliplatin (2 mg/ml) No breakthrough up to 240 minutes
• Paclitaxel (6 mg/ml) No breakthrough up to 240 minutes
• Paraplatin (10 mg/ml) No breakthrough up to 240 minutes
• Pemetrexed (25 mg/ml) No breakthrough up to 240 minutes
• Pertuzumab (30 mg/ml) No breakthrough up to 240 minutes
• Raltitrexed (0.5 mg/ml) No breakthrough up to 240 minutes
• Retrovir (10 mg/ml) No breakthrough up to 240 minutes
• Rituximab (10 mg/ml) No breakthrough up to 240 minutes
• Temsirolimus (25 mg/ml) No breakthrough up to 240 minutes
• Trastuzumab (21 mg/ml) No breakthrough up to 240 minutes
• ThioTEPA (10 mg/ml) No breakthrough up to 240 minutes
• Topotecan HCL (1 mg/ml) No breakthrough up to 240 minutes
• Triclosan (2 mg/ml) No breakthrough up to 240 minutes
• Trisonex (1 mg/ml) No breakthrough up to 240 minutes
• Vincrinstine Sulfate (1 mg/ml) No breakthrough up to 240 minutes
• Vinblastine (1 mg/ml) No breakthrough up to 240 minutes
• Vinorelbine (10 mg/ml) No breakthrough up to 240 minutes
• Zoledronic Acid (0.8 mg/ml Carmustine (3.3 m g/ml) permeation occurred at 128.5 minutes
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。